Discontinuing Treatment Against Medical Advice: The Role of Perceived Autonomy Support From Providers in Relapsing-Remitting Multiple Sclerosis
- PMID: 29771271
- DOI: 10.1093/abm/kay035
Discontinuing Treatment Against Medical Advice: The Role of Perceived Autonomy Support From Providers in Relapsing-Remitting Multiple Sclerosis
Abstract
Background: Long-term medication adherence is problematic among patients with chronic medical conditions. To our knowledge, this was the first study to examine factors associated with nonadherence among patients with relapsing-remitting multiple sclerosis who discontinue disease-modifying treatments against medical advice.
Purpose: To examine differences in perceived provider autonomy support between disease-modifying treatment-adherent relapsing-remitting multiple sclerosis patients and relapsing-remitting multiple sclerosis patients who discontinued disease-modifying treatments against medical advice.
Methods: Self-report questionnaires and a neurologic exam were administered to demographically matched adherent (n = 50) and nonadherent (n = 79) relapsing- remitting multiple sclerosis patients from the Midwest and Northeast USA.
Results: Adherent patients reported greater perceived autonomy support from their treatment providers, F(1, 124) = 28.170, p < .001, partial η2 = .185. This difference persisted after controlling for current multiple sclerosis healthcare provider, education, disease duration, Expanded Disability Status Scale, perceived barriers to adherence, and prevalence of side effects, F(1, 121) = 9.61, p = .002, partial η2 = .074. Neither depressive symptoms, F(1, 124) = 1.001, p > .05, partial η2 = .009, nor the occurrence of a major depressive episode, χ2(1, N = 129) = .288, p > .05, differed between adherent and nonadherent patients.
Conclusions: Greater perceived autonomy support from treatment providers may increase adherence to disease-modifying treatments among patients who discontinue treatment against medical advice. Results may inform interventions for patients who discontinue treatment against medical advice.
Keywords: Against medical advice; Autonomy support; Medication nonadherence; Multiple sclerosis.
© Society of Behavioral Medicine 2018. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates.Neurodegener Dis Manag. 2020 Aug;10(4):257-266. doi: 10.2217/nmt-2020-0016. Epub 2020 May 22. Neurodegener Dis Manag. 2020. PMID: 32438857 Review.
-
Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.Mult Scler Relat Disord. 2019 Aug;33:13-21. doi: 10.1016/j.msard.2019.04.036. Epub 2019 May 9. Mult Scler Relat Disord. 2019. PMID: 31132664 Clinical Trial.
-
Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study.Int J Pharm Pract. 2023 Apr 10;31(2):198-205. doi: 10.1093/ijpp/riac081. Int J Pharm Pract. 2023. PMID: 36738264
-
Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data.J Neurosci Nurs. 2010 Oct;42(5 Suppl):S5-9. doi: 10.1097/jnn.0b013e3181ee1240. J Neurosci Nurs. 2010. PMID: 21049828 Review.
-
A pilot study to improve adherence among MS patients who discontinue treatment against medical advice.J Behav Med. 2016 Apr;39(2):276-87. doi: 10.1007/s10865-015-9694-6. Epub 2015 Nov 12. J Behav Med. 2016. PMID: 26563147 Clinical Trial.
Cited by
-
Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier.Neurol Ther. 2018 Dec;7(2):179-187. doi: 10.1007/s40120-018-0118-8. Epub 2018 Nov 9. Neurol Ther. 2018. PMID: 30414084 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources